Modifications in the steps and ingredients of the manufacturing process of immune globulin have changed the world of immune therapy.
The healthcare reform laws include new strict reporting guidelines for the medical industry, and physicians need to ensure that what is reported is correct to protect their practice.
The FDA’s new strategy to ensure that the safety of certain drugs outweighs the risks they potentially pose to patients continues to evolve as the healthcare industry takes an active role in current and future REMS requirements.
Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.
With the push to reduce the cost of healthcare yet improve the quality and efficiency of care, Accountable Care Organizations could be a solution.
We're answering questions about switching from intravenous immune globulin therapy to subcutaneous immune globulin therapy, copayment for self-injectables, the definition of homebound patients and more.
While there has been virtually no decrease in the number of medical misdiagnoses in the U.S., awareness of the problem is growing, resulting in increased recommendations for reducing the incidence rate.
What effects can insurance companies, physicians, hospitals and the biopharmaceutical industry expect from the gradual implementation of healthcare reform law?
Discussing reimbursement codes and insurance coverage of Fluzone and off-label uses for Rituxan.
Clarifying some commonly held misunderstandings about healthcare reimbursement.
To err may be human, but when it comes to medication mistakes, the consequences can be deadly. Remedying the problem will require coordinated interventions across all sectors of the healthcare system.